US drug group Amgen has offered to acquire its Danish partner Nuevolution for USD 167 million - an increase by 169 percent relative to Nuevolution's closing price Tuesday this week. The board recommends that the shareholders accept the offer.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.